Serum Lipids, Apolipoproteins, and Mortality among Coronary Artery Disease Patients
Table 4
HRs for all-cause and cardiovascular mortality according to different levels of TC, non-HDL-C, or TC/HDL-C.
Variables
Number of deaths
Person-years
Hazard ratios (95% confidence intervals)
All-cause mortality
CVD mortality
Total
CVD
Model 1a
Model 2b
Model 3c
Model 1a
Model 2b
Model 3c
TC (mg/dL)
<150
43
29
1317
1.00
1.00
1.00
1.00
1.00
1.00
150–199
60
45
2843
0.69 (0.46–1.03)
0.71 (0.45–1.08)
0.71 (0.47–1.08)
0.76 (0.47–1.23)
0.80 (0.49–1.32)
0.81 (0.49–1.32)
200–239
35
31
1325
1.14 (0.72–1.82)
1.29 (0.80–2.07)
1.29 (0.80–2.07)
1.54 (0.91–2.59)
1.80 (1.05–3.10)
1.79 (1.04–3.09)
≥240
9
8
512
0.78 (0.37–1.61)
0.82 (0.39–1.75)
0.78 (0.37–1.67)
1.05 (0.48–2.34)
1.17 (0.51–2.68)
1.14 (0.50–2.60)
for trend
0.083
0.053
0.051
0.034
0.013
0.014
Non-HDL-C (mg/dL)
<100
27
18
921
1.00
1.00
1.00
1.00
1.00
1.00
100–129
45
34
1581
1.06 (0.66–1.71)
1.15 (0.71–1.88)
1.12 (0.68–1.82)
1.19 (0.67–2.11)
1.32 (0.74–2.38)
1.29 (0.72–2.32)
130–159
32
25
1792
0.67 (0.40–1.13)
0.71 (0.41–1.21)
0.70 (0.41–1.20)
0.79 (0.43–1.46)
0.84 (0.45–1.58)
0.84 (0.45–1.58)
160–189
32
27
1027
1.38 (0.82–2.32)
1.52 (0.89–2.59)
1.49 (0.87–2.55)
1.76 (0.96–3.22)
2.03 (1.09-3.79)
2.00 (1.08–3.74)
≥190
11
9
675
0.88 (0.43–1.80)
0.97 (0.47–2.02)
0.92 (0.44–1.92)
1.09 (0.48–2.45)
1.23 (0.53–2.85)
1.18 (0.51–2.73)
for trend
0.07
0.06
0.07
0.07
0.04
0.04
TC/HDL ratio
Quartile 1
36
27
1474
1.00
1.00
1.00
1.00
1.00
1.00
Quartile 2
30
21
1482
0.93 (0.57–1.51)
0.93 (0.56–1.54)
0.89 (0.54–1.48)
0.86 (0.48–1.53)
0.82 (0.46–1.49)
0.80 (0.44–1.44)
Quartile 3
34
26
1471
1.08 (0.67–1.73)
1.09 (0.67–1.78)
1.08 (0.66–1.75)
1.10 (0.64–1.89)
1.06 (0.60–1.84)
1.05 (0.60–1.83)
Quartile 4
47
39
1570
1.62 (1.04–2.52)
1.53 (0.96–2.43)
1.53 (0.96–2.43)
1.75 (1.06–2.88)
1.56 (0.92–2.64)
1.56 (0.92–2.65)
for trend
0.061
0.15
0.12
0.035
0.11
0.094
Model 1 was adjusted for age, gender, education, marriage, leisure-time physical activity, smoking, and alcohol drinking.
bModel 2 was adjusted for model 1 covariates plus type, severity, duration, and treatment of CAD, history of diabetes, history of heart failure, BMI, systolic blood pressure, glomerular filtration rate, and use of antihypertensive drugs, antidiabetic drugs, and antiplatelet drugs.
cModel 3 was adjusted for model 2 covariates plus use of cholesterol-lowering drugs.
